Traditional Chinese medicine compound composition for treating or preventing hepatic fibrosis and application of traditional Chinese medicine compound composition
The invention discloses a traditional Chinese medicine compound composition for treating or preventing hepatic fibrosis and application of the traditional Chinese medicine compound composition. The traditional Chinese medicine compound composition for treating or preventing hepatic fibrosis is prepared from, by weight, 15-31 parts of oriental wormwood, 10-31 parts of fructus forsythiae, 2.5-10 parts of prepared rhubarb, 5-15 parts of prepared polygonum multiflorum, 10-31 parts of radix paeoniae rubra and 3-8 parts of cassia twigs. , 5-12 parts by weight of fructus aurantii, 5-12 parts by weight of rhizoma atractylodis macrocephalae, 5-12 parts by weight of schisandra chinensis, 5-12 parts by weight of turtle shell and 3-10 parts by weight of raw liquorice. The traditional Chinese medicine compound composition can improve stage scores of mouse hepatic tissue fibrosis, obviously reduce serum levels of TBIL, DBIL, TBA, ALP, gamma-GT, ALT, AST, HA, P-III-P, IV-C and LN, and regulate serum contents of SOD, MDA and GSH, and has the effects of resisting oxidative stress and antagonizing hepatic tissue fibrosis..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 14. Okt. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
YAN SUQI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-10-14, Last update posted on www.tib.eu: 2023-10-16, Last updated: 2023-10-20 |
|---|
| Patentnummer: |
CN115177673 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017132452 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017132452 | ||
| 003 | DE-627 | ||
| 005 | 20231020095109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230614s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017132452 | ||
| 035 | |a (EPA)CN115177673 | ||
| 035 | |a (EPA)83515296 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a YAN SUQI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Traditional Chinese medicine compound composition for treating or preventing hepatic fibrosis and application of traditional Chinese medicine compound composition |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-10-14, Last update posted on www.tib.eu: 2023-10-16, Last updated: 2023-10-20 | ||
| 520 | |a The invention discloses a traditional Chinese medicine compound composition for treating or preventing hepatic fibrosis and application of the traditional Chinese medicine compound composition. The traditional Chinese medicine compound composition for treating or preventing hepatic fibrosis is prepared from, by weight, 15-31 parts of oriental wormwood, 10-31 parts of fructus forsythiae, 2.5-10 parts of prepared rhubarb, 5-15 parts of prepared polygonum multiflorum, 10-31 parts of radix paeoniae rubra and 3-8 parts of cassia twigs. , 5-12 parts by weight of fructus aurantii, 5-12 parts by weight of rhizoma atractylodis macrocephalae, 5-12 parts by weight of schisandra chinensis, 5-12 parts by weight of turtle shell and 3-10 parts by weight of raw liquorice. The traditional Chinese medicine compound composition can improve stage scores of mouse hepatic tissue fibrosis, obviously reduce serum levels of TBIL, DBIL, TBA, ALP, gamma-GT, ALT, AST, HA, P-III-P, IV-C and LN, and regulate serum contents of SOD, MDA and GSH, and has the effects of resisting oxidative stress and antagonizing hepatic tissue fibrosis. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a XIONG XIAOLI |4 aut | |
| 700 | 0 | |a ZHOU LISHAN |4 aut | |
| 700 | 0 | |a QIN HUAN |4 aut | |
| 700 | 0 | |a YI WEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 14. Okt. |
| 773 | 1 | 8 | |g year:2022 |g day:14 |g month:10 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83515296/publication/CN115177673A1?q=CN115177673 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 14 |c 10 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 14 |c 10 | ||